AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 31 min read$AUPH

TANG KEVIN purchased $3.1M of AUPH (indirect holdings)

TANG KEVIN (Chief Executive Officer) purchased 206,005 indirectly-held shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.28 ($3.15M total) on 2026-06-02.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jun 3, 2026, 1:54 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AUPH
Bullish
medium confidence
Mentioned
$AUPH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBullishLow
01

Why it matters

The disclosure updates ownership/behavior signals but does not introduce new company-specific business or trial outcomes.

02

Market read

Traders may treat as a mild sentiment input; it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The transaction is indirect and lacks context on motivations; traders should weigh it against broader clinical/regulatory timelines for Aurinia.

Relevance 6/10Novelty 6/10Timing: Filed June 2 (after-hours disclosure) for an open-market buy executed June 2

Background

The article is an SEC Form 4 insider transaction disclosure for Aurinia Pharmaceuticals (AUPH).

Company-level read

Ticker impact

$AUPHBullishMedium confidence
Context

AUPH CEO/10% owner Kevin Tang bought 206,005 shares in an open-market transaction worth about $3.15M, disclosed via Form 4.

Expected impact

Likely modest, short-lived sentiment lift; limited impact unless followed by additional news.

Evidence & confidence

The filing provides a concrete ownership change and transaction size, but it does not include new operational/clinical/regulatory information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine (e.g., personal liquidity planning) and may not reflect near-term fundamentals, especially without a 10b5-1 plan.

Key entities

  • issuer
    Aurinia Pharmaceuticals Inc.

    Subject of the Form 4 insider transaction; CEO/10% owner Kevin Tang purchased shares.

  • insider
    TANG KEVIN

    CEO, officer/director/10% owner who reported the open-market purchase.

Read at source← All news

Related articles

AUG 6
$AUPHMed

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.

thestarphoenix.com5 min
AUG 6
$AUPHMed

Aurinia Pharmaceuticals Inc. (AUPH): Results of Operations and Financial Condition

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_q22026earningsr.htm EX-99.1 Document Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress ROCKVILLE, Maryland and EDMONTON, Alberta – August 6, 2026 – A

SEC EDGAR 8-K6 min